

A.F.AF the French association against Friedreich ataxia is involved in a new trial

Pioglitazone trial

Investigator Dr Isabelle Husson Robert Debré (paediatric hospital) Paris .
isabelle.husson@rdb.ap-hop-paris.fr

This trial started on december 2008 the 16th. A new patient is enrolled every week. This trial is 2 years long for 40 patients , 20 patients are going to receive pioglitazone, 20 placebo.

Inclusion criteria : up to 25 years

to be able to walk 2 steps even with a walking device
, both genders

Exclusion criteria : severe cardiomyopathy

Pioglitazone is an oral antidiabetes medication which, according to PDr Rustin, may have a beneficial effect : stabilization and perhaps neurological improvement. on Friedreich ataxia
Other medication allowed : idebenone at a constant level.

A short stay in the hospital is planned every 6 months for a multidisciplinary evaluation.
A psychologist Jessica Save follows up patients and families.

European patients may be included in this trial but all the information and informed consent for children and parents must be legally translated into the native language of patients (I. Husson can offer this if but only if there are several patients from the same country)

There is no charge for hospitalisation and trial participation for European patients but they would have to pay for travelling to Paris , may be the national ataxian associations could help

Dr Isabelle Husson would like to include European patients so , please , get in touch with her by email , in English.

isabelle.husson@rdb.ap-hop-paris.fr